Skip to content

At ACADIA, we are committed to improving the lives of patients with neurological and related central nervous system disorders.

About Us

ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. More »


July 29, 2014
ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014

July 15, 2014
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer

More News »

Product Candidates

We have a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.   More »


Company Information

Investor's Kit Learn More: Pimavanserin Phase III Program for Parkinson's Disease Psychosis »
Investor Webcasts Investor Webcasts »
PDF Corporate Presentation »